Johnson and Johnson (JNJ) Actualités

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American...

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated...

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2...

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation...

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX®...

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PR...

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully...

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque...

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress PR...